Dyax Announces Marketing Authorization Application for DX-88 (ecallantide) Validated by EMA Learn More
Dyax and Sigma-Tau Announce Partnership to Develop and Commercialize Subcutaneous DX-88 (ecallantide) for HAE and Other Indications Outside US Learn More
Dyax Sells Rights to Xyntha® Royalty Stream to Paul Capital Healthcare for up to $12 Million Learn More
First-Ever Published Study Underscores Significant Economic Burden of HAE on Patients, Families and the Healthcare System Learn More
Dyax Announces New Developments Related to Phage Display-Discovered Drug Candidates Learn More
Dyax Features Comprehensive Financial Assistance Program On Enhanced Product Website for KALBITOR® (ecallantide)